Cefpirome Sulfate for Injection

This product is a β-lactamase-stable cephalosporin bactericidal antibiotic. It works by blocking the synthesis of the main cell wall polymer - peptidoglycan. Because it can quickly penetrate the bacterial cell wall and bind to the target enzyme (penicillin binding protein) with high affinity, it can have a bactericidal effect on a fairly broad spectrum of Gram-negative and Gram-positive pathogens at low concentration levels. This has been confirmed in numerous in vitro studies on hospital- and community-acquired pathogens worldwide, and recent studies have shown that its sensitivity has not changed. Many strains that are resistant to other injectable cephalosporins or aminoglycosides are still sensitive to this product. Antibacterial activity: The following are pathogens that are sensitive to cefpirome in vitro: Gram-positive bacteria: Staphylococcus aureus (including

The main ingredient of this product is cefpirome sulfate. Its chemical name is: (6R,7R)-7-[(Z)-2-(2-amino-4-thiazolyl)-2-methoxyiminoacetylamino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxy monosulfate.

This product is white to slightly yellow crystalline powder.

This product can be used to treat the following infections caused by unknown pathogens or known sensitive bacteria: lower respiratory tract infections (bronchopneumonia and lobar pneumonia); combined upper (pyelonephritis) and lower urinary tract infections; skin and soft tissue infections (cellulitis, skin abscesses and wound infections); infections in neutropenic patients; bacteremia/sepsis. Serious infections listed above.

This product is administered parenterally, and its dosage, administration method and course of treatment are determined by the severity of the infection, the sensitivity of the pathogen, the patient's condition and the renal function. The following dosages are recommended for patients with moderate to severe infections with normal renal function. For very serious cases of urinary tract, skin and soft tissue infections, the unit dose can be increased to 2.0 grams. Dosage for patients with impaired renal function: Cefpirome is mainly excreted through the kidneys, so the dose must be reduced in patients with impaired renal function to balance its slower excretion. Usage: Intravenous injection: Dissolve 1 vial of 1.0 or 2.0 grams of cefpirome powder in 10 ml or 20 ml of sterile water for injection, respectively, and then inject the solution directly into the vein or the distal end of the clamped infusion line within 3 to 5 minutes.

The following adverse reactions may be observed during cephalosporin treatment: Allergic reactions: allergic skin reactions; rash, urticaria, itching, drug fever; severe acute allergic reactions may occur: angioedema, bronchospasm, requiring emergency treatment. As with other cephalosporins, individual cases of bullous reactions such as erythema multiforme, Stevens-Johnson syndrome, and toxic epithelial necrolysis have also been reported. Effects on the gastrointestinal tract: nausea, vomiting, diarrhea; in rare cases, pseudomembranous colitis may occur (see Precautions). Effects on lung function: There is a possibility of interstitial pneumonia (with symptoms such as fever, cough, dyspnea, abnormal chest X-ray, eosinophilia, etc.) and PIE syndrome. If the above occurs,

This product is contraindicated for patients who are allergic to cephalosporins and should be used with caution by patients who are allergic to penicillin antibiotics.

Drug interactions: When this product is used in combination with sodium thiopental, the solution tends to become turbid quickly, so the combined use should be avoided; when used in combination with diphenhydramine hydrochloride, calcium iodide, and papaverine hydrochloride, precipitation may sometimes occur over time, so the two should be used quickly after combination; when used in combination with aminophylline, the potency of the drug tends to decrease significantly over time, so it should be used quickly after combination. Although there is no evidence that cefpirome affects renal function at normal therapeutic doses, it may enhance its nephrotoxic effects if used in combination with certain drugs (such as aminoglycosides). Probenecid can affect the renal tubular transport of cefpirome, thereby delaying its excretion and increasing its plasma concentration. Other interactions: Extremely

Keep away from light and in a cool place. Validity period: two years

1.0g (based on C22H22N6O5S2)

24 months

Suzhou Wanqing Pharmaceutical Co., Ltd.

• Founded in:

  2003-03-10

• Address:

  Room 625-53, 6th Floor, East Building, Incubation Building, No. 6, Beijing West Road, Taicang, Suzhou

• Tax NO.:

  913205857473146062

• Registered Funds:

  2 million yuan

• Email:

  Log in to view